home.social

#abbvie — Public Fediverse posts

Live and recent posts from across the Fediverse tagged #abbvie, aggregated by home.social.

  1. Why US multinationals keep choosing Ireland. It’s not just the tax or workforce – The Irish Times

    If you ask US multinationals why they choose Ireland as a base for investment, they’ll talk about the…
    #NewsBeep #News #Economy #AbbVie #Alphabet #Apple #Business #feargal-orourke #GileadSciences #ida-ireland #merck #Microsoft #stryker #UK #UnitedKingdom
    newsbeep.com/uk/684198/

  2. Analysis: Market Outlook for AbbVie Following Recent Earnings Performance

    📰 Original title: Watch: Why Investors Are Still Worried About AbbVie

    🤖 IA: It's clickbait ⚠️
    👥 Usuarios: It's clickbait ⚠️

    View full AI summary: killbait.com/en/analysis-marke

    #business #abbvie #inves...

  3. Analysis: Market Outlook for AbbVie Following Recent Earnings Performance

    📰 Original title: Watch: Why Investors Are Still Worried About AbbVie

    🤖 IA: It's clickbait ⚠️
    👥 Usuarios: It's clickbait ⚠️

    View full AI summary: killbait.com/en/analysis-marke

    #business #abbvie #inve...

  4. ¿Por qué AbbVie prevé ganancias récord en 2026 gracias a la inmunología? La farmacéutica supera las expectativas y anticipa un crecimiento sostenido impulsado por nuevos medicamentos sagaroja.com/es/blog/empresas/ #Abbvie #Farmacuticas #Inmunologa

  5. Bloomberg: #Alphabet #shares rally 6% in early trading as the company's strength in #search #advertising helped profit beat estimates. #AbbVie, #Colgate-Palmolive and #Schlumberger are slated to report later. #Stocks and the dollar edge higher. #markets

  6. 5 neuro data readouts to watch in the second half of 2024 — GSK moves to new HQ in return to central London — AbbVie led the way in paying doctors to pitch its drugs last year —bit.ly/w28kSd #clinicaltrials #neurology #gsk #london #abbvie #physicians #physicianpayments #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  7. AbbVie's tight grip on Humira market raises concerns about biosimilars—As biotech recovers, venture firms’ preferences appear to shift — Boehringer, Zealand heat up MASH race with strong phase II data—bit.ly/w28kSd #abbvie #humira #biosimilars #funding #mash #nash #boehringeringelheim #ipos #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  8. AbbVie (#ABBV) reported an actual EPS of $2.31, slightly higher than the forecasted $2.27. Additionally, its revenue beat expectations, with actual revenue at $12.31 billion compared to the forecasted $11.93 billion. #AbbVie #earnings

  9. Strong demand for Botox, generating $1.49 billion in quarterly revenue, persists despite intense competition. AbbVie's 2024 earnings per share forecast falls in the range of $11.05 - $11.25 billion, aligning with analyst estimates at the upper end of this range, specifically at $11.24. #AbbVie #FinancialResults #EarningsReport #Humira #ImmunologyProducts #Botox #RevenueForecast #2024Projection #MarketExpectations

  10. The negative outlook stemming from CVS Health's decision to delist Humira poses a challenge, but AbbVie aims to counter the lost revenue with new immunology products Skyrizi and Rinvoq. In its 2027 projection, AbbVie raised the revenue forecast for these drugs from $21 billion to $27 billion.#AbbVie #FinancialResults #EarningsReport #Humira #ImmunologyProducts #Botox #RevenueForecast #2024Projection #MarketExpectations

  11. AbbVie reported robust financial results, with earnings reaching $2.79 per share and revenue totaling $14.3 billion. This surpassed market expectations of $2.77 per share and $14.01 billion in revenue. Despite increased competition impacting Humira, one of the company's leading drugs, leading to a 41% YoY decline in Q4 sales to $3.30 billion, it still exceeded analyst estimates of $3.28 billion. #AbbVie #FinancialResults #EarningsReport #Humira #ImmunologyProducts #Botox #2024Projection

  12. How a #Drug Company Made $114 Billion by Gaming the US #Patent System
    Over the past 20 years, #AbbVie and its former parent company increased #Humira’s price about 30 times, most recently by 8% this month over 60% total to over $80,000 a year!
    nyti.ms/3HAC7Lr #healthcar

  13. Talk about the tail wagging the dog: #AbbVie is leaving both PhRMA and BIO because "there was...frustration that AbbVie’s vigorous #patent battles could spill over and damage the industry’s overall image." Man, when the trade orgs won't go to bat for you 🤣
    statnews.com/2022/12/15/abbvie #pharma